08.03.2024 • NewsSandozOphthalmologyBiosimilars

Sandoz Acquires Ophthalmology Franchise from Coherus

In a move to expand its ophthalmic platform, Sandoz, the former generics and biosimilars arm of Swiss drugmaker Novartis, has completed the acquisition of Coherus BioSciences’ subsidiary Coherus Ophthalmology for $170 million.

The deal, which adds the biosimilar Cimerli (ranibizumab-eqrn) to Sandoz's portfolio, includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.

Sandoz and Coherus entered into the transaction agreement in January 2024.

Keren Haruvi, president Sandoz North America said: “Today we further expand the Sandoz biosimilar portfolio, while advancing our mission in the US of pioneering patient access to more affordable and much-needed medicines. With the addition of Cimerli to our existing ophthalmology franchise, we can now offer even more treatment options for US patients with vision impairment and loss.”

Cimerli, is an anti-VEGF therapy, is indicated for the treatment of certain retinal diseases that, if left untreated, can cause vision loss.

© Shutterstock
© Shutterstock

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.